Literature DB >> 8772706

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.

M Roy1, R Dumaine, A M Brown.   

Abstract

BACKGROUND: Administration of the antihistamine terfenadine (Seldane) to patients may result in acquired long QT syndrome and ventricular arrhythmias. One human cardiac target is Kv1.5, which expresses the ultrarapid outward K+ current (Ikur) in atrium but may play only a minor role in ventricle. Another possible target is HERG, the human ether-a-go-go-related gene that expresses a delayed rectifier current (IKr) in human ventricle and produces hereditary long QT syndrome when defective. METHODS AND
RESULTS: We therefore heterologously expressed Kv1.5 and HERG in Xenopus oocytes to compare the sensitivity of each to terfenadine. We found that HERG was 10 times more sensitive than Kv1.5 to terfenadine block. The apparent Kd values for HERG and Kv1.5 currents were 350 nmol/L and 2.7 mumol/L, respectively. These Kd values compare well with values reported for terfenadine block of IKr and IKur currents in human atrial myocytes. The Kd value for HERG block is relevant to the toxicity of the antihistamine, since the clinical terfenadine concentrations in human plasma may reach the 100 nmol/L range.
CONCLUSIONS: Terfenadine carboxylate, the major metabolite of terfenadine, does not block either HERG or Kv1.5, which agrees with the hypothesis that the buildup of parent terfenadine is the likely explanation for its cardiotoxicity. We propose that the blocking of HERG by terfenadine explains the acquired long QT syndrome. HERG is likely to be the primary target for the known cardiotoxic effects of other, related antihistamines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8772706     DOI: 10.1161/01.cir.94.4.817

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  70 in total

1.  Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.

Authors:  A G Teschemacher; E P Seward; J C Hancox; H J Witchel
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

2.  Enhancement of HERG K+ currents by Cd2+ destabilization of the inactivated state.

Authors:  J P Johnson; J R Balser; P B Bennett
Journal:  Biophys J       Date:  1999-11       Impact factor: 4.033

Review 3.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Deciphering modern glucocorticoid cross-pharmacology using ancestral corticosteroid receptors.

Authors:  Jeffrey A Kohn; Kirti Deshpande; Eric A Ortlund
Journal:  J Biol Chem       Date:  2012-03-21       Impact factor: 5.157

5.  Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?

Authors:  Hua Rong Lu; An N Hermans; David J Gallacher
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 6.  Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.

Authors:  Nicole T Feric; Milica Radisic
Journal:  Adv Drug Deliv Rev       Date:  2015-05-05       Impact factor: 15.470

7.  Regulation of the human ether-a-gogo related gene (HERG) K+ channels by reactive oxygen species.

Authors:  M Taglialatela; P Castaldo; S Iossa; A Pannaccione; A Fresi; E Ficker; L Annunziato
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

Review 8.  Molecular diversity and regulation of renal potassium channels.

Authors:  Steven C Hebert; Gary Desir; Gerhard Giebisch; Wenhui Wang
Journal:  Physiol Rev       Date:  2005-01       Impact factor: 37.312

9.  Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome?

Authors:  R Dumaine; C Antzelevitch
Journal:  J Mol Cell Cardiol       Date:  2006-07-25       Impact factor: 5.000

Review 10.  Principles of safety pharmacology.

Authors:  M K Pugsley; S Authier; M J Curtis
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.